Sign in

Dimitrios L. Wagner

@dlwagner.bsky.social
2.2K followers 992 following 48 posts

Physician & science enthusiast @BCMHouston @ChariteBerlin @BIHregeneration // Genome Editing and Immunology // 50% of @immunoboys.bsky.social / @dlwagnerlabs.bsky.social /

PostsRepliesMedia
Reposted by Dimitrios L. Wagner
Julia Carnevale @juliacarnevale.bsky.social · 13/08/2026
Very excited to share my lab's first major paper, led by postdoc Qi Liu @gladstoneinst.bsky.social @ucsanfrancisco.bsky.social executing the first ever genome-wide in vivo screens for genetic modifications to enhance human T cell therapies for solid tumors. www.nature.com/articles/s41...
nature.com
In vivo genome-wide CRISPR screens of human T cells in solid tumours - Nature
An in vivo model that is able to recover human T cells from solid tumours can identify targets to help improve CAR T cell antitumour activity.
1209
Reposted by Dimitrios L. Wagner
Waggoner Lab @labwaggoner.bsky.social · 06/08/2026
Review @bloodjournal.bsky.social @dlwagner.bsky.social Promises and potential pitfalls of in vivo CAR gene therapy ashpublications.org/blood/articl...
131
Reposted by Dimitrios L. Wagner
FOCIS - Federation of Clinical Immunology Societies @focisimmunology.bsky.social · 11/06/2026
Come see our presidential keynote presentation from FOCIS President Ignacio Anegon in Salon 8! 📣📣 #Focis2026
031
Reposted by Dimitrios L. Wagner
Daniel Gorelick @danielgorelick.bsky.social · 03/06/2026
Paying peer reviewers works. Expanded Fast & Fair experiment @biologyopen.bsky.social: • 5.5 vs 37.7 working days to decision with reviews • ~3 vs ~9 reviewer invitations per manuscript • no reduction in editor-assessed review quality • similar acceptance rates www.biorxiv.org/content/10.6...
Scatter plot showing that Fast & Fair peer review reached first decision with reviews much faster than conventional peer review: mean 5.5 versus 37.7 working days. Most Fast & Fair manuscripts met the 7-working-day target, while conventional manuscripts were slower and more variable, up to 116 working days.
8232117
Reposted by Dimitrios L. Wagner
FOCIS - Federation of Clinical Immunology Societies @focisimmunology.bsky.social · 12/03/2026
🚨 Don’t miss the upcoming joint FOCIS & IUIS Virtual Symposium 💡 Immune-Mediated Inflammatory Diseases, New Mechanisms, and Therapeutic Options 📆 Thursday, May 7, 2026 | 4:00 - 5:30 PM (London); 10:00 - 11:30 AM (Chicago) Register now: zurl.co/7MGet
021
Reposted by Dimitrios L. Wagner
Dorien Pastoors @dpastoors.bsky.social · 21/01/2026
Rotation PhD student @emiliedevet.bsky.social in our lab made the Dish soap protocol work (on the first attempt) for a nuclear target with Dawn (the US version of dreft/fairy ) and thereby extended the dish soap protocol to a version for across the atlantic 🤩 @tothovalab.bsky.social #hemesky
0135
Reposted by Dimitrios L. Wagner
bioRxiv Immunology @biorxiv-immuno.bsky.social · 16/01/2026
Distinct EBV-Associated Phenotypes Due to a Novel Homozygous Missense Variant in CD27. www.biorxiv.org/content/10.64898/20…
021
Reposted by Dimitrios L. Wagner
Emma Dann @emmamarydann.bsky.social · 05/01/2026
Together with @ronghuizhu.bsky.social, we are thrilled to present our new perturb-seq study of 22M primary CD4+ T cells, across donors and timepoints – the result of a decade-long collaboration between the Marson @marsonlab.bsky.social and Pritchard @jkpritch.bsky.social labs 🧵 tinyurl.com/gwt2025
tinyurl.com
Genome-scale perturb-seq in primary human CD4+ T cells maps context-specific regulators of T cell programs and human immune traits
Gene regulatory networks encode the fundamental logic of cellular functions, but systematic network mapping remains challenging, especially in cell states relevant to human biology and disease. Here, ...
26529
Reposted by Dimitrios L. Wagner
Vijay G. Sankaran @bloodgenes.bsky.social · 18/12/2025
Terrific to have our paper, led by @tjflemin.bsky.social, featured as a plenary article in @bloodjournal.bsky.social today: ashpublications.org/blood/articl...
1215
Reposted by Dimitrios L. Wagner
Klebanoff Lab @klebanofflab.bsky.social · 18/12/2025
🚨This week in @natcomms.nature.com: We resolve an enduring enigma in T cell biology—how TCR binding to p/HLA triggers intracellular signaling. CryoEM in native environment reveals a 'jack-in-the-box' mechanism! Collab btw @rockefeller.edu @mskcancercenter.bsky.social rdcu.be/eUPPl
rdcu.be
The resting and ligand-bound states of the membrane-embedded human T-cell receptor–CD3 complex
Nature Communications - The T-cell receptor (TCR) activation mechanism has remained uncertain. Here, the authors present molecular structures for the apo and ligand-bound human TCR–CD3...
0185
Reposted by Dimitrios L. Wagner
bioRxiv Immunology @biorxiv-immuno.bsky.social · 13/12/2025
Clinical development of gene edited tacrolimus-resistant Treg (FKBP12KO-Treg) to enable simultaneous immunosuppression and support of immune regulation www.biorxiv.org/content/10.64898/20…
052
Reposted by Dimitrios L. Wagner
Peggy Goodell @goodell-lab.bsky.social · 12/12/2025
Original work here ⬇️, led by the inimitable Lorenzo Brunetti and Michael Gundry. This work became foundational in the field.
cell.com
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Brunetti et al. show that specific loss of NPM1c from the cytoplasm leads to downregulation of HOX genes and differentiation in NPM1 mutant AML. Blocking NPM1c nuclear export by XPO1 inhibition reduce...
141
Reposted by Dimitrios L. Wagner
Peggy Goodell @goodell-lab.bsky.social · 12/12/2025
Today's the print release of a #RibackLab and #GoodellLab collaboration— we’re excited to share the visual story behind the science, including the dramatic artwork that inspired how we thought about aberrant function of NPM1c - which occurs in about 1 in 3 adult acute myeloid leukemias (#AML).
1188
Reposted by Dimitrios L. Wagner
Eric Topol @erictopol.bsky.social · 08/12/2025
A big advance, folks, for off-the-shelf, universal, engineered (base-edited) T cells achieving complete response vs incurable leukemia in several patients www.nejm.org/doi/full/10....
332080
Reposted by Dimitrios L. Wagner
Lennard Ostendorf @lostendorf.bsky.social · 06/12/2025
Our case report of a patient developing drug-induced systemic sclerosis after bleomycin exposure – still showing antibodies after 5 years. Nicely done Philipp 🎉 #rheumsky authors.elsevier.com/sd/article/S...
0122
Reposted by Dimitrios L. Wagner
Waggoner Lab @labwaggoner.bsky.social · 05/12/2025
Extrusive and cohesive cohesin cooperate to repair double-strand breaks in DNA @science.org @albertomarin.bsky.social @gerlichlab.bsky.social @imbavienna.bsky.social www.science.org/doi/10.1126/... www.science.org/doi/10.1126/... www.science.org/doi/10.1126/...
0309
Reposted by Dimitrios L. Wagner
Ross Wilson @rosswilsonlab.org · 02/12/2025
Big news! Our team developed Neuro-PERC, a non-viral CRISPR delivery platform for genome editing of the brain. In our new preprint - bit.ly/NeuroPERC_pre - we report efficient editing in multiple models & species, including field-first results in large animals (pigs) 🧵👇
bit.ly
264
Reposted by Dimitrios L. Wagner
Leif Erik Sander 🇪🇺🇺🇦 @sanderlab.bsky.social · 01/12/2025
On this #WorldAIDSday @cgaebler.bsky.social, Olaf Penack & teams at #CharitéBerlin report the #SecondBerlinPatient cured of #HIV after heterozygous CCR5Δ32 HSCT. The study opens exciting perspectives for immune-based #HIVCure strategies for longterm ART-free viral control and ultimately cure.
nature.com
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation - Nature
Nature - Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation
0298
Reposted by Dimitrios L. Wagner
Dr. Stephanie @punkrockscience.bsky.social · 24/11/2025
Today’s xkcd made me cry. In a good way. xkcd.com/3172/
3664631961
Reposted by Dimitrios L. Wagner
immunoboys @immunoboys.bsky.social · 13/11/2025
Adapting the 10x workflow to detect EBV reads, Younis et al show that EBV-transcribing B cells are increased in SLE patients, especially among CD27+CD21low B cells. They have autoreactive BCRs and are more poised for antigen-presentation. 2025 Sci Transl Med 🧪 ⑂ www.science.org/doi/10.1126/...
Workflow of EBV-seq
082
Reposted by Dimitrios L. Wagner
Lennard Ostendorf @lostendorf.bsky.social · 05/11/2025
What mechanisms drive checkpoint inhibitor-associated interstitial nephritis (ICI-AIN)? In our preprint, we identify CD8 T cells as a central player, inducing a proinflammatory myeloid cell state by IFNg and structuring lymphoid aggregates by CXCL13. www.biorxiv.org/content/10.1... 1/n #Nephsky 🧪
CD8 T cells produce IFNg and CXCL13 in TLS
164
Reposted by Dimitrios L. Wagner
Waggoner Lab @labwaggoner.bsky.social · 12/11/2025
A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors @natcomms.nature.com www.nature.com/articles/s41...
053
Reposted by Dimitrios L. Wagner
Josh Riback @superscijew.bsky.social · 04/11/2025
(1/10) How do diverse leukemia mutations converge on the same molecular program? In #RibackLab first manuscript @cp-cell.bsky.social, collaboration with @goodell-lab.bsky.social shows that disparate mutations rewire shared protein networks to form nuclear condensates called C-bodies.
75323
Reposted by Dimitrios L. Wagner
immunoboys @immunoboys.bsky.social · 20/10/2025
Ubiquitinylation is more complex than just a signal for proteasomal degradation: Linear ubiquitinylation of Methionine-1 is important for NFkB signalling. LOF of the Deubiquitinylase OTULIN leads to an autoinflammatory disease with a TNF positive feedback loop. 🧪 ⑂ 1/2
1136
Reposted by Dimitrios L. Wagner
Jacob Corn @jcornlab.bsky.social · 24/10/2025
Ever noticed that #CRISPR editing results differ between cells? Awesome PhD student Moritz Schlapansky developed "scOUT-seq" to measure single cell transcriptomes + editing. 1.2 million cells, 74 cell types, living 🐭. Cell subtypes differ wildly from bulk average! www.biorxiv.org/content/10.1...
biorxiv.org
Cell-stereotyped DNA repair outcomes are widespread during genome editing
Genome editing outcomes are governed by DNA repair pathways that vary with cell type and state. We developed scOUT-seq (single-cell Outcomes Using Transcript sequencing), a scalable approach that join...
31811
Reposted by Dimitrios L. Wagner
The Buck Institute for Research on Aging @buckinstitute.org · 16/10/2025
A new subspecialty takes off! Astroimmunology is focused on the effects of #spaceflight on the #immunesystem and defines avenues for countermeasures. A bonus: the work will also inform research on #aging @natrevimmunol.nature.com evimmunol.nature.com www.buckinstitute.org/news/a-hitch...
buckinstitute.org
A hitchhiker’s guide to the galaxy of space immunology
Buck scientists help define the scope of Astroimmunology   With the advent of commercial spaceflight, an increasing number of people may be heading into space in the coming years.  Some will even get ...
072
Reposted by Dimitrios L. Wagner
Oded Rechavi @odedrechavi.bsky.social · 15/10/2025
BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 (thread 👇)
56495185
Reposted by Dimitrios L. Wagner
Daniel Ibrahim @danielibrahim.bsky.social · 16/10/2025
What is a promoter? And how does it work? We very happy to share our latest work trying to understand enhancer-promoter compatibility. I am very excited about the results of @blanka-majchrzycka.bsky.social, which changed the way I think about promoters www.biorxiv.org/content/10.1...
biorxiv.org
Enhancer-promoter compatibility is mediated by the promoter-proximal region
Gene promoters induce transcription in response to distal enhancers. How enhancers specifically activate their target promoter while bypassing other promoters remains unclear. Here, we find that the p...
217374
Reposted by Dimitrios L. Wagner
Connor Tou @connorjtou.bsky.social · 15/10/2025
Honored to be part of the 2025 #STATWunderkinds! Grateful for the many supportive mentors, colleagues, and friends with special shoutout to @bkleinstiver.bsky.social. Full list: www.statnews.com/wunderkinds/ @statnews.com @mitdeptofbe.bsky.social @mgbresearch.bsky.social @harvardmed.bsky.social
152
Dimitrios L. Wagner @dlwagner.bsky.social · 14/10/2025
“ ‘Off the shelf’ Treg may soon be… on the shelf. “ - awesome quote by Prof. Fadi Issa. Check out our new story: 👇 www.nature.com/articles/s41... One week after the Nobel prize for Treg 🍀
040
Dimitrios L. Wagner @dlwagner.bsky.social · 13/10/2025
“Good things take time” Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function! A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social
0183
Reposted by Dimitrios L. Wagner
Waggoner Lab @labwaggoner.bsky.social · 13/10/2025
HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model @natcomms.nature.com @dlwagner.bsky.social @bcmhouston.bsky.social www.nature.com/articles/s41...
0123
Dimitrios L. Wagner @dlwagner.bsky.social · 12/10/2025
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸 We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸 Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
0217
Reposted by Dimitrios L. Wagner
Kristina Šekrst @epiphenomenal.bsky.social · 11/10/2025
Accurate. #academia #academy #philsky #philosophysky #philosophy #science
439885
Reposted by Dimitrios L. Wagner
bioRxiv Immunology @biorxiv-immuno.bsky.social · 08/10/2025
TCR activation impairs CAR-T cytotoxicity against separate target cells www.biorxiv.org/content/10.1101/202…
042
Reposted by Dimitrios L. Wagner
DL Wagner Genome Engineering Labs @dlwagnerlabs.bsky.social · 05/10/2025
Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community! Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor (BEKI) + posters by Ana, Lily, Jonas and Laura
073
Reposted by Dimitrios L. Wagner
Lorenz Bastian @lbastianmd.bsky.social · 28/09/2025
Excited to share our preprint📯: We introduce #IntegrateALL, an open-source RNA-seq pipeline for interpretable molecular diagnostics in acute lymphoblastic leukemia!🧬 Big thanks to Nadine Wolgast & team @ www.uksh.de , catchall-kfo5010.com! See: doi.org/p7k5 and 🧵
131
Reposted by Dimitrios L. Wagner
Lorenz Bastian @lbastianmd.bsky.social · 28/09/2025
Big shoutout to the whole group who made #IntegrateALL possible - especially @alinamh.bsky.social, Thomas Beder and Claudia Baldus at www.catchall-kfo5010.com
catchall-kfo5010.com
CATCH ALL KFO 5010
Within the new Clinical Research Unit (CRU) “CATCH ALL – towards a cure for all adults and children with Acute Lymphoblastic Leukemia (ALL)”, funded by the German Research Foundation (DFG)…
022
Reposted by Dimitrios L. Wagner
bioRxiv Immunology @biorxiv-immuno.bsky.social · 25/09/2025
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors www.biorxiv.org/content/10.1101/202…
011
Reposted by Dimitrios L. Wagner
Laura Hartmann @lmhartmann.bsky.social · 23/09/2025
Check out one of our latest stories about combining our non viral knock-in strategy with integrases for an efficient, targeted integration of transgenes >8kb in human T cells! ‘One-pot’ PASTA: programmable and site specific transgene addition - all in just one reaction 🫕
062
Reposted by Dimitrios L. Wagner
Daniel Ibrahim @danielibrahim.bsky.social · 19/09/2025
This has been such a great collaboration with @dlwagnerlabs.bsky.social! You really need to check it out One-pot PASTA 🍝 - a one-step protocol to knock-in large transgenes. I feel tempted to think about one-pot PIZZA 🍕 next! First authors Isabell and @therealjonaskath.bsky.social were amazing!!
061
Reposted by Dimitrios L. Wagner
Jonas Kath @therealjonaskath.bsky.social · 19/09/2025
Super-large targeted Knock-Ins in primary T cells, with multigene inserts >8kb, in a single reaction. HOW?? 🙀 Combine simple CRISPR-HDR & Integrases for one-pot PASTA🍝 = Programmable And Site-specific Transgene Addition. 😎
1112
Dimitrios L. Wagner @dlwagner.bsky.social · 19/09/2025
You like engineering T cells, but you are missing the right flavor? Check out 'one-pot' PASTA recipe 🔥🍝: www.biorxiv.org/content/10.1101/2025.09.10.675267v1 We combined a unique mix of CRISPR knock-in with serine integrases for easy-to-adopt 𝐏rogrammable 𝐀nd 𝐒ite-specific 𝐓ransgene 𝐀ddition 🧪
biorxiv.org
Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases
Current gene transfer methods often lack the precision, versatility, or efficiency when integrating large transgenes, limiting the ability to engineer therapeutic T-cells with more complex payloads. H...
1428
Dimitrios L. Wagner @dlwagner.bsky.social · 18/09/2025
🚀 In preparation for releasing two new stories, @therealjonaskath.bsky.social is revisiting the journey so far—sharing the lab’s last six papers. What a ride it’s been… 🙌🧬🧪🧫
061
Reposted by Dimitrios L. Wagner
Tobias Bexte @bextetobias.bsky.social · 17/09/2025
🚨 Paper alert! "Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
jitc.bmj.com
Next-generation multiplex-edited CAR-NK cells: more edits, more power?
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ c...
051
Reposted by Dimitrios L. Wagner
immunoboys @immunoboys.bsky.social · 11/09/2025
Plasmacytoid dendritic cells can transition to become cDC2s under to influence of TNF, while type-I interferon reduces TNFR expression and thereby inhibits transition. These transitioned cDC2 seem fully functional. 🧪 ⑂ Hornero et al 2025 in Nat Immunol www.nature.com/articles/s41...
0175
Reposted by Dimitrios L. Wagner
Ming Tommy Tang @tommytang.bsky.social · 08/09/2025
23 tools to work with (single-cell) TCR/BCR-seq immune repertoire data 🧵 👇
1104
Reposted by Dimitrios L. Wagner
John Doench @johndoench.bsky.social · 07/09/2025
Doomscrolling pause to chat CRISPR libraries! Preprint describes our new, data-driven approach to combine on-target and off-target predictions much more intelligently for *selecting* guides, which we use to develop our newest Cas9 knockout library, Jacquere. Thread: www.biorxiv.org/content/10.1...
biorxiv.org
Balancing off-target and on-target considerations for optimized Cas9 CRISPR knockout library design
The continued development of high-dimensional CRISPR screen readouts, such as single-cell RNA sequencing and high-content imaging, necessitates compact libraries to enable functional interrogation at ...
27524
Reposted by Dimitrios L. Wagner
immunoboys @immunoboys.bsky.social · 06/09/2025
Horisberger et al separate Lupus nephritis patients in 3 groups by blood: healthy-like, interferon-dominant and CD8 T cell-dominant. The CD8 T cell-dominant group had the highest biopsy activity score and highest response rate after 1 year; the healthy-like the most chronic damage. 🧪 ⑂ #NephSky 1/
1116
Reposted by Dimitrios L. Wagner
immunoboys @immunoboys.bsky.social · 02/09/2025
A synonymous mitochondrial variant is negatively selected against in short-lived CD8 effectors – How? The variant changes tRNA pairing from Watson-Crick-Franklin to wobble, thereby reducing translational efficiency in high energy demand. 🧪 ⑂ Lareau et al – 2025 www.pnas.org/doi/10.1073/...
062